New studies are constantly evolving the field of lymphoma research, with trials continuously striving to find more effective treatments. At the 2017 National Cancer Research Institute (NCRI) Conference in Liverpool, UK, Graham Collins, MA, MBBs, MRCP, FRCPath, DPhil of the Oxford University Hospitals NHS Foundation Trust, Oxford, UK, spoke to us about some of the most anticipated upcoming trial results in the field of lymphoma treatment. Among them include the ECHELON-1 trial (NCT01712490), comparing ABVD with AVD plus brentuximab vedotin in the treatment of advanced stage Hodgkin lymphoma, and the new antibody-drug conjugate ADCT-301, which targets CD25. Dr Collins reviews some of the initial data that has been released, and discusses the pros and cons to the drugs.
New lymphoma drug studies show promise
